Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 May 18;82(12):1907–1913. doi: 10.1054/bjoc.2000.1203

Vinorelbine – a clinical review

R K Gregory 1, I E Smith 1
PMCID: PMC2363259  PMID: 10864196

Full Text

The Full Text of this article is available as a PDF (88.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adenis A., Vanlemmens L., Fournier C., Hecquet B., Bonneterre J. Does induction chemotherapy with a mitoxantrone/vinorelbine regimen allow a breast-conservative treatment in patients with operable locoregional breast cancer? A French Northern Oncology Group trial in 105 patients. French Northern Oncology Group. Breast Cancer Res Treat. 1996;40(2):161–169. doi: 10.1007/BF01806211. [DOI] [PubMed] [Google Scholar]
  2. Ashizawa T., Miyoshi K., Asada M., Kobayashi E., Okabe M., Morimoto M., Gomi K., Hirata T. [Antitumor activity of navelbine (vinorelbine ditartrate), a new vinca alkaloid analog]. Gan To Kagaku Ryoho. 1993 Jan;20(1):59–66. [PubMed] [Google Scholar]
  3. Baldini E., Tibaldi C., Ardizzoni A., Salvati F., Antilli A., Portalone L., Barbera S., Romano F., De Marinis F., Migliorino M. R. Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study. Italian Lung Cancer Task Force (FONICAP). Br J Cancer. 1998 Jun;77(12):2367–2370. doi: 10.1038/bjc.1998.393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Besenval M., Delgado M., Demarez J. P., Krikorian A. Safety and tolerance of Navelbine in phase I-II clinical studies. Semin Oncol. 1989 Apr;16(2 Suppl 4):37–40. [PubMed] [Google Scholar]
  5. Binet S., Chaineau E., Fellous A., Lataste H., Krikorian A., Couzinier J. P., Meininger V. Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules. Int J Cancer. 1990 Aug 15;46(2):262–266. doi: 10.1002/ijc.2910460220. [DOI] [PubMed] [Google Scholar]
  6. Binet S., Fellous A., Lataste H., Krikorian A., Couzinier J. P., Meininger V. In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence. Semin Oncol. 1989 Apr;16(2 Suppl 4):5–8. [PubMed] [Google Scholar]
  7. Boré P., Rahmani R., van Cantfort J., Focan C., Cano J. P. Pharmacokinetics of a new anticancer drug, navelbine, in patients. Comparative study of radioimmunologic and radioactive determination methods. Cancer Chemother Pharmacol. 1989;23(4):247–251. doi: 10.1007/BF00451650. [DOI] [PubMed] [Google Scholar]
  8. Bruno S., Puerto V. L., Mickiewicz E., Hegg R., Texeira L. C., Gaitan L., Martinez L., Fernandez O., Otero J., Kesselring G. Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience. Am J Clin Oncol. 1995 Oct;18(5):392–396. doi: 10.1097/00000421-199510000-00006. [DOI] [PubMed] [Google Scholar]
  9. Canobbio L., Boccardo F., Pastorino G., Brema F., Martini C., Resasco M., Santi L. Phase-II study of Navelbine in advanced breast cancer. Semin Oncol. 1989 Apr;16(2 Suppl 4):33–36. [PubMed] [Google Scholar]
  10. Colucci G., Gebbia V., Galetta D., Riccardi F., Cariello S., Gebbia N. Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM). Br J Cancer. 1997;76(11):1509–1517. doi: 10.1038/bjc.1997.586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cros S., Wright M., Morimoto M., Lataste H., Couzinier J. P., Krikorian A. Experimental antitumor activity of Navelbine. Semin Oncol. 1989 Apr;16(2 Suppl 4):15–20. [PubMed] [Google Scholar]
  12. Cvitkovic E., Izzo J. The current and future place of vinorelbine in cancer therapy. Drugs. 1992;44 (Suppl 4):36–69. doi: 10.2165/00003495-199200444-00005. [DOI] [PubMed] [Google Scholar]
  13. Debal V., Morjani H., Millot J. M., Angiboust J. F., Gourdier B., Manfait M. Determination of vinorelbine (Navelbine) in tumour cells by high-performance liquid chromatography. J Chromatogr. 1992 Oct 2;581(1):93–99. doi: 10.1016/0378-4347(92)80451-u. [DOI] [PubMed] [Google Scholar]
  14. Depierre A., Lemarie E., Dabouis G., Garnier G., Jacoulet P., Dalphin J. C. A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol. 1991 Apr;14(2):115–119. doi: 10.1097/00000421-199104000-00004. [DOI] [PubMed] [Google Scholar]
  15. Devizzi L., Santoro A., Bonfante V., Viviani S., Balzarini L., Valagussa P., Bonadonna G. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease. Ann Oncol. 1994 Nov;5(9):817–820. doi: 10.1093/oxfordjournals.annonc.a059010. [DOI] [PubMed] [Google Scholar]
  16. Dieras V., Extra J. M., Bellissant E., Espie M., Morvan F., Pierga J. Y., Mignot L., Tresca P., Marty M. Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method. J Clin Oncol. 1996 Dec;14(12):3097–3104. doi: 10.1200/JCO.1996.14.12.3097. [DOI] [PubMed] [Google Scholar]
  17. Dubos C., Prévost J. N., Brun J., Rousselot P. Infarctus myocardique et vinorelbine. Rapport d'un cas. Rev Mal Respir. 1991;8(3):299–300. [PubMed] [Google Scholar]
  18. Felip E., Del Campo J. M., Bodi R., Vera R., Casado S., Rubio D. Cisplatin and vinorelbine followed by radiotherapy in the treatment of stage III-B non-small-cell lung cancer patients. Am J Clin Oncol. 1997 Aug;20(4):404–406. doi: 10.1097/00000421-199708000-00017. [DOI] [PubMed] [Google Scholar]
  19. Frasci G., Panza N., Comella P., Nicolella G. P., Natale M., Pacilio C., Gravina A., Caputi V., Botti G., Comella G. Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study. Ann Oncol. 1997 Oct;8(10):1045–1048. doi: 10.1023/a:1008218306355. [DOI] [PubMed] [Google Scholar]
  20. Fumoleau P., Delgado F. M., Delozier T., Monnier A., Gil Delgado M. A., Kerbrat P., Garcia-Giralt E., Keiling R., Namer M., Closon M. T. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 1993 Jul;11(7):1245–1252. doi: 10.1200/JCO.1993.11.7.1245. [DOI] [PubMed] [Google Scholar]
  21. Furuse K., Kubota K., Kawahara M., Ogawara M., Kinuwaki E., Motomiya M., Nishiwaki Y., Niitani H., Sakuma A. A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Japan Vinorelbine Lung Cancer Study Group. Lung Cancer. 1994 Dec;11(5-6):385–391. doi: 10.1016/0169-5002(94)92167-9. [DOI] [PubMed] [Google Scholar]
  22. García-Conde J., Lluch A., Martin M., Casado A., Gervasio H., De Oliveira C., De Pablo J. L., Gorostiaga J., Girón G. C., Cervantes A. Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol. 1994 Nov;5(9):854–857. doi: 10.1093/oxfordjournals.annonc.a059019. [DOI] [PubMed] [Google Scholar]
  23. Gebbia V., Caruso M., Valenza R., Testa A., Cannata G., Verderame F., Cipolla C., Curto G., Oliveri D., Chiarenza M. Vinorelbine plus cisplatinum for the treatment of stage IIIB and IV non small cell lung carcinoma. Anticancer Res. 1994 May-Jun;14(3B):1247–1249. [PubMed] [Google Scholar]
  24. Gershenson D. M., Burke T. W., Morris M., Bast R. C., Guaspari A., Hohneker J., Wharton J. T. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer. Gynecol Oncol. 1998 Sep;70(3):404–409. doi: 10.1006/gyno.1998.5130. [DOI] [PubMed] [Google Scholar]
  25. Gridelli C., Perrone F., Gallo C., De Marinis F., Ianniello G., Cigolari S., Cariello S., Di Costanzo F., D'Aprile M., Rossi A. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. Eur J Cancer. 1997 Mar;33(3):392–397. doi: 10.1016/s0959-8049(97)89011-9. [DOI] [PubMed] [Google Scholar]
  26. Gridelli C., Perrone F., Ianniello G. P., Brancaccio L., Iaffaioli R. V., Curcio C., D'Aprile M., Cioffi R., Cigolari S., Rossi A. Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study. Gruppo Oncologico Centro-Sud-Isole. J Clin Oncol. 1998 Apr;16(4):1414–1419. doi: 10.1200/JCO.1998.16.4.1414. [DOI] [PubMed] [Google Scholar]
  27. Haldar S., Jena N., Croce C. M. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci U S A. 1995 May 9;92(10):4507–4511. doi: 10.1073/pnas.92.10.4507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. JOHNSON I. S., WRIGHT H. F., SVOBODA G. H., VLANTIS J. Antitumor principles derived from Vinca rosea Linn. I. Vincaleukoblastine and leurosine. Cancer Res. 1960 Aug;20:1016–1022. [PubMed] [Google Scholar]
  29. Jehl F., Debs J., Herlin C., Quoix E., Gallion C., Monteil H. Determination of navelbine and desacetylnavelbine in biological fluids by high-performance liquid chromatography. J Chromatogr. 1990 Jan 26;525(1):225–233. doi: 10.1016/s0378-4347(00)83397-6. [DOI] [PubMed] [Google Scholar]
  30. Jehl F., Quoix E., Leveque D., Pauli G., Breillout F., Krikorian A., Monteil H. Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography. Cancer Res. 1991 Apr 15;51(8):2073–2076. [PubMed] [Google Scholar]
  31. Kobayashi S., Sakai T., Dalrymple P. D., Wood S. G., Chasseaud L. F. Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. Arzneimittelforschung. 1993 Dec;43(12):1367–1377. [PubMed] [Google Scholar]
  32. Le Chevalier T., Brisgand D., Douillard J. Y., Pujol J. L., Alberola V., Monnier A., Riviere A., Lianes P., Chomy P., Cigolari S. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 1994 Feb;12(2):360–367. doi: 10.1200/JCO.1994.12.2.360. [DOI] [PubMed] [Google Scholar]
  33. Levêque D., Jehl F., Quoix E., Breillout F. Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin. J Clin Pharmacol. 1992 Dec;32(12):1096–1098. [PubMed] [Google Scholar]
  34. Levêque D., Quoix E., Dumont P., Massard G., Hentz J. G., Charloux A., Jehl F. Pulmonary distribution of vinorelbine in patients with non-small-cell lung cancer. Cancer Chemother Pharmacol. 1993;33(2):176–178. doi: 10.1007/BF00685338. [DOI] [PubMed] [Google Scholar]
  35. Marquet P., Lachatre G., Debord J., Eichler B., Bonnaud F., Nicot G. Pharmacokinetics of vinorelbine in man. Eur J Clin Pharmacol. 1992;42(5):545–547. doi: 10.1007/BF00314866. [DOI] [PubMed] [Google Scholar]
  36. Masters G. A., Hoffman P. C., Drinkard L. C., Samuels B. L., Golomb H. M., Vokes E. E. A review of ifosfamide and vinorelbine in advanced non-small cell carcinoma of the lung. Semin Oncol. 1998 Feb;25(1 Suppl 2):8–14. [PubMed] [Google Scholar]
  37. Morris M., Brader K. R., Levenback C., Burke T. W., Atkinson E. N., Scott W. R., Gershenson D. M. Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. J Clin Oncol. 1998 Mar;16(3):1094–1098. doi: 10.1200/JCO.1998.16.3.1094. [DOI] [PubMed] [Google Scholar]
  38. Mouridsen H. T. Systemic therapy of advanced breast cancer. Drugs. 1992;44 (Suppl 4):17–69. doi: 10.2165/00003495-199200444-00003. [DOI] [PubMed] [Google Scholar]
  39. Paintrand M. R., Pignot I. Navelbine: an ultrastructural study of its effects. J Electron Microsc (Tokyo) 1983;32(2):115–124. [PubMed] [Google Scholar]
  40. Rahmani R., Martin M., Barbet J., Cano J. P. Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine). Cancer Res. 1984 Dec;44(12 Pt 1):5609–5613. [PubMed] [Google Scholar]
  41. Rittenberg C. N., Gralla R. J., Rehmeyer T. A. Assessing and managing venous irritation associated with vinorelbine tartrate (Navelbine) Oncol Nurs Forum. 1995 May;22(4):707–710. [PubMed] [Google Scholar]
  42. Romero A., Rabinovich M. G., Vallejo C. T., Perez J. E., Rodriguez R., Cuevas M. A., Machiavelli M., Lacava J. A., Langhi M., Romero Acuña L. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol. 1994 Feb;12(2):336–341. doi: 10.1200/JCO.1994.12.2.336. [DOI] [PubMed] [Google Scholar]
  43. Santomaggio C., Tucci E., Rinaldini M., Algeri R., Righi R., Pepi F., Ghezzi P., Andrei A., Bellezza A. Carboplatin and vinorelbine in the treatment of advanced non-small-cell lung cancer: a multicenter phase II study. Am J Clin Oncol. 1998 Feb;21(1):67–71. doi: 10.1097/00000421-199802000-00015. [DOI] [PubMed] [Google Scholar]
  44. Smith T. J., Hillner B. E., Neighbors D. M., McSorley P. A., Le Chevalier T. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol. 1995 Sep;13(9):2166–2173. doi: 10.1200/JCO.1995.13.9.2166. [DOI] [PubMed] [Google Scholar]
  45. Spielmann M., Dorval T., Turpin F., Antoine E., Jouve M., Maylevin F., Lacombe D., Rouesse J., Pouillart P., Tursz T. Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol. 1994 Sep;12(9):1764–1770. doi: 10.1200/JCO.1994.12.9.1764. [DOI] [PubMed] [Google Scholar]
  46. Terenziani M., Demicheli R., Brambilla C., Ferrari L., Moliterni A., Zambetti M., Caraceni A., Martini C., Bonadonna G. Vinorelbine: an active, non cross-resistant drug in advanced breast cancer. Results from a phase II study. Breast Cancer Res Treat. 1996;39(3):285–291. doi: 10.1007/BF01806156. [DOI] [PubMed] [Google Scholar]
  47. Tononi A., Panzini I., Oliverio G., Pasquini E., Gianni L., Nicolini M., Ravaioli A. Vinorelbine chemotherapy in non small cell lung cancer: experience in elderly patients. J Chemother. 1997 Aug;9(4):304–308. doi: 10.1179/joc.1997.9.4.304. [DOI] [PubMed] [Google Scholar]
  48. Twelves C. J., Dobbs N. A., Curnow A., Coleman R. E., Stewart A. L., Tyrrell C. J., Canney P., Rubens R. D. A phase II, multicentre, UK study of vinorelbine in advanced breast cancer. Br J Cancer. 1994 Nov;70(5):990–993. doi: 10.1038/bjc.1994.435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Van Belle S. J., De Smet M., Monsaert C., Geerts F., Storme G. A., Massart D. L. High-performance liquid chromatographic determination of navelbine in MO4 mouse fibrosarcoma cells and biological fluids. J Chromatogr. 1992 May 8;576(2):351–357. doi: 10.1016/0378-4347(92)80211-8. [DOI] [PubMed] [Google Scholar]
  50. Veronesi A., Crivellari D., Magri M. D., Cartei G., Mansutti M., Foladore S., Monfardini S. Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients. Eur J Cancer. 1996 Sep;32A(10):1809–1811. doi: 10.1016/0959-8049(96)00190-6. [DOI] [PubMed] [Google Scholar]
  51. Vogel C., O'Rourke M., Winer E., Hochster H., Chang A., Adamkiewicz B., White R., McGuirt C. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol. 1999 Apr;10(4):397–402. doi: 10.1023/a:1008364222793. [DOI] [PubMed] [Google Scholar]
  52. Wang L. G., Liu X. M., Kreis W., Budman D. R. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol. 1999;44(5):355–361. doi: 10.1007/s002800050989. [DOI] [PubMed] [Google Scholar]
  53. Weber B. L., Vogel C., Jones S., Harvey H., Hutchins L., Bigley J., Hohneker J. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol. 1995 Nov;13(11):2722–2730. doi: 10.1200/JCO.1995.13.11.2722. [DOI] [PubMed] [Google Scholar]
  54. Weisenberg R. C. Microtubule formation in vitro in solutions containing low calcium concentrations. Science. 1972 Sep 22;177(4054):1104–1105. doi: 10.1126/science.177.4054.1104. [DOI] [PubMed] [Google Scholar]
  55. Wozniak A. J., Crowley J. J., Balcerzak S. P., Weiss G. R., Spiridonidis C. H., Baker L. H., Albain K. S., Kelly K., Taylor S. A., Gandara D. R. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1998 Jul;16(7):2459–2465. doi: 10.1200/JCO.1998.16.7.2459. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES